Drug Type Small molecule drug |
Synonyms 9-β-D-ribofuranosyl-9H-purin-6-ol, 9-β-D-ribofuranosylhypoxanthine, beta-Inosine + [50] |
Target |
Action stimulants |
Mechanism NGFB stimulants(Beta-nerve growth factor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 1981), |
Regulation- |
Molecular FormulaC10H12N4O5 |
InChIKeyUGQMRVRMYYASKQ-KQYNXXCUSA-N |
CAS Registry58-63-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Angina Pectoris | China | 01 Jan 1981 | |
Heart Failure | China | 01 Jan 1981 | |
Hepatitis | China | 01 Jan 1981 | |
Optic Atrophy | China | 01 Jan 1981 | |
Retinitis | China | 01 Jan 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 1 | United States | 20 Jun 2016 | |
Acute Lung Injury | Preclinical | China | 25 Jul 2025 | |
Acute Lung Injury | Preclinical | China | 25 Jul 2025 |
Phase 3 | 587 | ntrivueeru(oxpjsjkzbz) = jseqgmbqki ahsluxrnzb (jzkpibtyun ) View more | Negative | 14 Sep 2021 | |||
Placebo | ntrivueeru(oxpjsjkzbz) = rhasptubpf ahsluxrnzb (jzkpibtyun ) View more | ||||||
Phase 2 | 48 | (Inosine) | kcvsidcnda = yejeoebyfv lhgydllkuj (binjpldqmh, nehpnwyhix - hpbysyxpfc) View more | - | 18 Feb 2021 | ||
Placebo (Placebo) | kcvsidcnda = pblihugiit lhgydllkuj (binjpldqmh, cktkbrfxzk - clczadeakn) View more | ||||||
Phase 3 | serum urate positive | procollagen type-I N-terminal propeptide (P1NP) | β-C-terminal telopeptide of type I collagen (β-CTX) | 120 | Inosine 500mg twice daily | uivudpxuup(okhoecgpwo) = There was no difference in P1NP between groups over the six months nefxfcrkfj (jrsodnzapx ) View more | Negative | 06 Nov 2020 | |
Phase 3 | 298 | (Inosine) | wgeyudzbow(fxcgaqgntu) = rxrtttvooj xdzgxkplgy (onzcuxyvqh, druocwjajr - njoqxzltus) View more | - | 28 Jul 2020 | ||
Placebo (Placebo) | wgeyudzbow(fxcgaqgntu) = kmknhdnakh xdzgxkplgy (onzcuxyvqh, zudrgtaqxs - eqbawsvbky) View more | ||||||
Phase 1 | 32 | meoennqqve = nhfxkqogrp rfxrjraeze (zagbuavdaa, jtoibgxjoi - clwftqgxkn) View more | - | 02 Oct 2017 | |||
Phase 1 | - | 18 | (Inosine Fed) | eeamxzfjdu(hiquklajwm) = dztlsqurjl tngejkjekg (nptvhjbwlb, 0.7) View more | - | 24 Feb 2017 | |
(Inosine Fasted) | eeamxzfjdu(hiquklajwm) = uhxfbdcwim tngejkjekg (nptvhjbwlb, 0.6) View more | ||||||
Not Applicable | Parkinson Disease uric acid | - | pummaxbidg(awhmswwnsx) = wlilcvxors gyleyfbfev (xqhniibdhh ) | - | 15 Oct 2015 | ||
Phase 2 | 75 | Placebo ([A:]Placebo) | yijqddbask = wwawfmdfcc qepwtcfafc (drwyqxhpfz, krbvlgrgbn - aylrslhrsl) View more | - | 05 Jun 2014 | ||
([B:]Mild) | yijqddbask = ccjvjawiya qepwtcfafc (drwyqxhpfz, gapicpplui - aloevjzhaa) View more | ||||||
Phase 2 | Parkinson Disease serum urate | - | Placebo | qfnjrkmahu(gxrpbypdqj) = mcssmqgyme mnavuufqyh (mamttfkwpx ) | - | 08 Apr 2014 | |
Inosine (mild dosage) | qfnjrkmahu(gxrpbypdqj) = nknhcukbgm mnavuufqyh (mamttfkwpx ) | ||||||
Phase 2 | Parkinson Disease serum urate | - | Placebo | prnfispmvb(cnwcntqnkw) = vffcklrwkw guidqiksxm (dougtovriv ) View more | Positive | 01 Oct 2013 | |
Inosine to mildly elevate serum urate (6.1-7.0 mg/dL) | zrlxlkappb(iawahxeuys) = ioevnnrkji wetquhjdfr (eaekpjjoru ) View more |